Shaan C. Gandhi, M.D., D.Phil.

Director, Northpond Ventures

Shaan C. Gandhi is a Director at Northpond Ventures on the firm’s biotechnologies team. Shaan is a Board Director at public and private companies including Aro Biotherapeutics, CAMP4 Therapeutics, Candel Therapeutics (NASDAQ: CADL), DICE Therapeutics (NASDAQ: DICE), Garuda Therapeutics, Mestag Therapeutics, Parthenon Therapeutics, StrideBio, Totus Medicines, and Vigil Neuroscience (NASDAQ: VIGL). Previously, Shaan was a Principal at the Longwood Fund, where he created and invested in life sciences companies, including Pyxis Oncology (NASDAQ: PYXS), an antibody-drug conjugate and monoclonal antibody oncology company, which he co-founded and served as President. Prior to Longwood, he was an attending hospitalist at Massachusetts General Hospital, where he also did his residency in internal medicine. He holds an M.D. from Harvard Medical School; an MBA from Harvard Business School, where he was a Baker Scholar; a D.Phil. in medical oncology from the University of Oxford, where he was a Rhodes Scholar; and a B.S. with honors in biochemistry from Case Western Reserve University. Shaan is the Vice President of the Suffolk District Medical Society, the professional medical society of Boston, and a Trustee of the Boston Medical Library.